In early January 2021, the U.S. Department of Justice’s (“the DOJ”) Antitrust Division (“the Division”) announced a Deferred Prosecution Agreement (“DPA”) with Argos USA LLC (“Argos” or “the Company”).
The Department of Justice (DOJ) Antitrust Division has obtained its first criminal indictment based on an illegal conspiracy between two companies that agreed not to solicit each other’s employees — a so-called “no-poach” agreement.
We recently reported several milestones and accomplishments from the inaugural year of the Antitrust Division’s Procurement Collusion Strike Force.
The intersection of government contracting and antitrust law keeps making the news.
On September 3, 2020, the Antitrust Division of the U.S. Department of Justice (the “Division”) issued an updated version of its Merger Remedies Manual (“Manual”).
The U.S. Department of Justice’s Antitrust Division reaffirmed its endorsement of leniency initiatives both on the domestic and international front by lauding congressional efforts to reauthorize the Antitrust Criminal Penalty Enhancement and Reform Act (ACPERA) and pushing forward international cooperation guidelines as part of a multinational working group.
On July 9, 2020, the U.S. Supreme Court announced that it would review the Federal Trade Commission’s authority to seek restitution in federal court for consumers who have been harmed by fraud and other misconduct in the marketplace.
Class actions in the pork and cattle industry foreshadow probable antitrust enforcement and defense strategies against the backdrop of COVID-19, which has caused meat processing plant closures, severe disruptions to the supply chain of consumer meat, and an increase in prices at your local grocery store.
In a speech at the American Bar Association Antitrust Law Section’s International Cartel Conference in San Francisco last week, Deputy Assistant Attorney General Richard A. Powers reaffirmed the Antitrust Division’s commitment to its mission of deterring, detecting, and prosecuting criminal antitrust conduct…
The DOJ’s Antitrust Division (“Division”) recently announced a significant policy change — that we covered in depth here — that will afford non-leniency companies the opportunity to seek mitigation…
On May 30, 2019, the DOJ’s Antitrust Division charged Heritage Pharmaceuticals Inc., a generic pharmaceutical company, for conspiring with its competitors to fix prices, rig bids, and allocate…